CCA
ABUS icon

Carrera Capital Advisors’s Arbutus Biopharma ABUS Stock Holding History

Carrera Capital Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
257,167
+5,008
+2% +$22K 0.18% 87
2026
Q1 		$1.13M Buy
+252,159
New +$1.1M 0.17% 85

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Carrera Capital Advisors's ABUS Position: Q2 2026 in Review

Carrera Capital Advisors increased its Arbutus Biopharma (ABUS) stake by 2% in Q2 2026, buying an estimated $22K and bringing the position to 257,167 shares worth $1.23M. The position accounts for 0.18% of the portfolio, ranked #87.

Carrera Capital Advisors first reported a position in ABUS in Q1 2026 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Carrera Capital Advisors held 257,167 shares of Arbutus Biopharma worth $1.23M as of Q2 2026.
  • Carrera Capital Advisors bought 5,008 Arbutus Biopharma shares in Q2 2026, an estimated $22K.
  • Arbutus Biopharma made up 0.18% of Carrera Capital Advisors's portfolio in Q2 2026, its #87 holding.
  • Carrera Capital Advisors first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Carrera Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.